Aktis Oncology Expands Clinical Enrollment for Actinium-Based Radiopharmaceuticals

Recently, Aktis Oncology of the United States disclosed the latest expanded enrollment arrangements for two clinical studies of innovative targeted radiopharmaceuticals based on Actinium-225. While continuing to advance the established dose-escalation trials, the company has added dedicated supplementary enrollment cohorts at selected dose levels for AKY-1189 targeting Nectin-4 and AKY-2519 targeting B7-H3, respectively, aiming to comprehensively observe the safety, tolerability, and preliminary antitumor activity of the drugs in specific patient populations, and to accumulate detailed data for subsequent large-scale clinical development.

In terms of specific clinical progress, AKY-1189 targeting Nectin-4 is currently undergoing in-depth evaluation in the Phase 1b portion of the NECTINIUM-2 study, with indications primarily covering locally advanced or metastatic urothelial carcinoma and other related solid tumors. The study has officially initiated supplementary enrollment at the 6 MBq dose level, with plans to enroll up to 30 patients to further characterize the clinical profile at this dose; meanwhile, AKY-2519 targeting B7-H3 is being evaluated for efficacy in metastatic castration-resistant prostate cancer in the Phase 1b portion of the BActinium-1 study, and at the 9 MBq dose level, expanded enrollment of up to 30 patients per cohort is being conducted separately for patients with and without prior Pluvicto treatment.

In addition to continuously accelerating clinical trials, Aktis Oncology has also achieved a key breakthrough in building an autonomous radiopharmaceutical supply chain. The company's own Good Manufacturing Practice (GMP) facility in Boston, Massachusetts, has now officially commenced drug production, and the company is proceeding to fully incorporate this manufacturing site into the clinical trial supply and manufacturing system for the two core candidate drugs through a clinical trial application amendment, achieving deep synergy from research and development to production.

According to the company's strategic plan, the proprietary GMP facility is expected to officially begin supplying drugs for clinical trials in the first half of 2027, thereby effectively supplementing the existing external contract manufacturing and isotope supply networks. Industry analysis notes that as the potential of targeted radioisotope therapy continues to unfold in the field of precision oncology, radiopharmaceutical companies ensuring the safety and stability of critical medical isotope supply chains through self-built manufacturing facilities is becoming an important milestone in advancing advanced nuclear medicine toward commercial maturity.

Disclaimer: Information republished from partner media, institutions or other websites is provided for reference and communication purposes only. It does not imply endorsement of its views or verification of its accuracy. Please contact us if any content infringes rights or requires correction.